MRK vs STRO · P/E 33, rev $65.01B vs rev $62.0M
Merck & Company Inc (MRK) versus Sutro Biopharma (STRO) — a side-by-side from cached financials, not a winner call.
Merck & Company Inc (MRK) is a drug manufacturers - general company listed on NYSE. It is led by Rob Davis.
Sutro Biopharma (STRO) is a biotechnology company listed on NASDAQ.
Latest reported MRK revenue for 2025-12-31 was $65.01B. Net income was $18.25B. Revenue was up 1.3% from 2024-12-31 to 2025-12-31. MRK currently screens at market cap $285.12B and trailing P/E 32.5.
Latest reported STRO revenue for 2024-12-31 was $62.0M. Net income was -$227.5M. Revenue was down 59.6% from 2023-12-31 to 2024-12-31. STRO currently screens at market cap $470.8M.
MRK currently screens at market cap $285.12B and trailing P/E 32.5. STRO currently screens at market cap $470.8M.
Not investment advice. Open the MRK and STRO stock pages for the full models.
Not investment advice.